Jazz Pharmaceuticals secured accelerated FDA approval for dordaviprone (Modeyso), the first systemic treatment targeting recurrent H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain cancer impacting children. Acquired through Jazz's $935 million purchase of Chimerix earlier in 2025, the oral imipridone marks a pivotal advancement for this underserved patient population, offering a novel therapeutic option where none previously existed.